Moolec Science SA

Moolec Science SA(MLEC)股票分析

$0.850

0.000 (0.00%)收盤時

Loading chart…
最高
0.850
開盤
0.850
成交量加權均價
—
成交量
0.00
市值
40.57M
最低
0.850
成交金額
0.00
企業價值/稅息折舊攤銷前利潤(TTM)
0.00

Moolec Science SA is a science-based food ingredient company. The Company operates an integrated platform encompassing research & development (R&D), manufacturing, and regulatory capabilities that span from molecular design to validation in both fermenter and field environments. It operates across the United States, Europe, and South America. The Company advances its molecular farming programs in crops such as soy and safflower to produce proteins and lipids with animal-like functionality and plant-based cost structures. It is developing a precision fermentation facility in Finland, under the SynBio Powerlabs brand, which will be dedicated to producing target proteins, enzymes, and other biomolecules using optimized microbial and cellular systems. Its product portfolio includes GLASO, PIGGY SOOY, VALORASOY, and MYCOFOOD. Its GLASO, a safflower-derived oil rich in functional lipids, is being used in formulations for small-animal feed.

AI 分析 of Moolec Science SA (MLEC)

賣出

Moolec Science SA (MLEC) is not a good buy right now. The current price is $0.85, which is significantly down 79.47% year-to-date and 91.63% over the past year. The RSI is at an extremely low 10.62, indicating the stock is oversold, but this does not guarantee a rebound. The gross margin is negative at -17.81%, reflecting ongoing financial struggles. Additionally, the company's debt to equity ratio is alarmingly high at 789.74%, posing a serious risk to financial stability. While there was a recent surge in stock price due to a reverse stock split and increased shareholder interest, the overall performance and financial health suggest caution. The main risk is the high debt level, which could hinder recovery efforts and investor confidence.

估值指標

Moolec Science SA(MLEC)目前預期本益比為 0.00,5 年平均預期本益比為 -6.20。

預期本益比

高估
5 年均值 P/E
-6.20
目前P/E
0.00
高估
-1.34
低估
-11.06

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
-6.44
目前EV/EBITDA
0.00
高估
0.90
低估
-13.78

預期股價營收比

合理
5 年均值 P/S
9.15
目前P/S
0.07
高估
25.82
低估
-7.52

Alphio AI 對 MLEC 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%MLEC

$29.13

情境價格

基

基準

基準 · 50%MLEC

$22.46

情境價格

悲

悲觀

悲觀 · 25%MLEC

$17.06

情境價格

事件時間軸

2026-07-15 (ET)

10:30:00

Moolec Science SA Trading Halted Due to Volatility Trading Pause

2026-05-14 (ET)

09:20:00

Moolec Science Completes 2026 GLASO Commercial Planting Campaign

2026-04-29 (ET)

09:10:00

Moolec Science Completes First Phase of GLASO1 Industrialization

2026-04-07 (ET)

08:20:00

Moolec Science Successfully Expresses Bovine Myoglobin in Pea Seeds

2026-02-18 (ET)

09:40:00

Moolec Science SA Trading Halted Due to Volatility Trading Pause

資訊

MLEC 常見問題 —— 由 Alphio AI 解答

Moolec Science SA is a science-based food ingredient company. The Company operates an integrated platform encompassing research & development (R&D), manufacturing, and regulatory capabilities that span from molecular design to validation in both fermenter and field environments. It operates across the United States, Europe, and South America. The Company advances its molecular farming programs in crops such as soy and safflower to produce proteins and lipids with animal-like functionality and plant-based cost structures. It is developing a precision fermentation facility in Finland, under the SynBio Powerlabs brand, which will be dedicated to producing target proteins, enzymes, and other biomolecules using optimized microbial and cellular systems. Its product portfolio includes GLASO, PIGGY SOOY, VALORASOY, and MYCOFOOD. Its GLASO, a safflower-derived oil rich in functional lipids, is being used in formulations for small-animal feed. It operates in the Consumer Non-Cyclicals sector.

Moolec Science SA (MLEC) is not a good buy right now. The current price is $0.85, which is significantly down 79.47% year-to-date and 91.63% over the past year. The RSI is at an extremely low 10.62, indicating the stock is oversold, but this does not guarantee a rebound. The gross margin is negative at -17.81%, reflecting ongoing financial struggles. Additionally, the company's debt to equity ratio is alarmingly high at 789.74%, posing a serious risk to financial stability. While there was a recent surge in stock price due to a reverse stock split and increased shareholder interest, the overall performance and financial health suggest caution. The main risk is the high debt level, which could hinder recovery efforts and investor confidence.

暫無貼文

註冊或登入後參與討論

相關文章

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易